The Chemours Company (CC) — Fair Value Analysis

Base-case fair value (P50): $17.61 · Current price: $18.89 · Verdict: Fairly Valued

The Verdict on CC

Our Monte Carlo simulations indicate CHEMOURS (CC) is currently Fairly Valued. The stock trades at $18.89, narrowly below our median fair value (P50) of $17.61. This marginal -6.8% difference suggests CC's present valuation is largely consistent with its fundamental outlook when considering thousands of forward-looking scenarios. While not presenting a significant discount or premium, this "Fairly Valued" verdict is a key output from our probabilistic framework, which accounts for various market and operational uncertainties.

How CC stacks up against peers

Analyzing CC within its competitive landscape reveals a weak quality tier in terms of operational and financial health. While our simulation points to a Fairly Valued status at $18.89 relative to the $17.61 median, this weak tier suggests underlying vulnerabilities compared to sector peers. Investors considering the modest -6.8% should factor in this foundational health assessment. A strong fundamental position typically underpins more robust fair value assessments and offers greater downside protection in adverse scenarios, which is not the case for CC's current standing.

What this means for investors

For investors, the Fairly Valued assessment of CC at $18.89, with a median fair value of $17.61 and a -6.8% gap, suggests limited immediate catalysts from a valuation perspective. Given the company's weak quality tier, any potential upside scenario may carry increased risk relative to stronger companies. Conversely, a downside scenario could be exacerbated by these operational and financial health challenges. To fully understand the probabilistic distribution of outcomes, including a detailed bear and bull case, sign up for a free FairCurve account. This allows you to track CC's fair value daily and receive instant re-valuations as new fundamentals are released.